Lasting effects of dopamine receptor agonists upon striatal dopamine release in free-moving rats: an in vivo voltammetric study. 1994

J H Abraini, and T Fechtali, and J C Rostain
Laboratoire de Physiopathologie Intégrée et Cellulaire, CNRS URA 1630, Faculté de Médecine Nord, Marseille, France.

It is now well known that dopamine (DA) receptors agonists can reduce striatal DA release. These compounds are generally thought to produce short-term effects. However, in a recent in vivo study we have reported that the D1/D2 receptor agonist apomorphine might induce decrements in striatal DA release that lasted several hours. In order to establish whether the effect of apomorphine was idiosyncratic or extended to other DA receptor agonists, we have investigated the effects of the selective D1 receptor agonist SKF 38393 and of the selective D2 receptor agonist LY 171555 upon striatal DA release using differential pulse voltammetry and multi-fibre carbon electrodes selective for DA. Results support that these DA receptor agonists can reduce DA release for several hours. The effects of SKF 38393 and of LY 171555 would be DA receptor-mediated since they can be blocked by the selective D1 receptor antagonist SCH 23390 and the selective D2 receptor antagonist sulpiride respectively. These findings are discussed at the light of current literature including methodological and biological data.

UI MeSH Term Description Entries
D008297 Male Males
D009068 Movement The act, process, or result of passing from one place or position to another. It differs from LOCOMOTION in that locomotion is restricted to the passing of the whole body from one place to another, while movement encompasses both locomotion but also a change of the position of the whole body or any of its parts. Movement may be used with reference to humans, vertebrate and invertebrate animals, and microorganisms. Differentiate also from MOTOR ACTIVITY, movement associated with behavior. Movements
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004567 Electrodes, Implanted Surgically placed electric conductors through which ELECTRIC STIMULATION is delivered to or electrical activity is recorded from a specific point inside the body. Implantable Electrodes,Implantable Stimulation Electrodes,Implanted Electrodes,Implanted Stimulation Electrodes,Electrode, Implantable,Electrode, Implantable Stimulation,Electrode, Implanted,Electrode, Implanted Stimulation,Electrodes, Implantable,Electrodes, Implantable Stimulation,Electrodes, Implanted Stimulation,Implantable Electrode,Implantable Stimulation Electrode,Implanted Electrode,Implanted Stimulation Electrode,Stimulation Electrode, Implantable,Stimulation Electrode, Implanted,Stimulation Electrodes, Implantable,Stimulation Electrodes, Implanted
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014677 Pharmaceutical Vehicles A carrier or inert medium used as a solvent (or diluent) in which the medicinally active agent is formulated and or administered. (Dictionary of Pharmacy, 1986) Pharmaceutical Vehicle,Vehicle, Pharmaceutical,Vehicles, Pharmaceutical
D015647 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine A selective D1 dopamine receptor agonist used primarily as a research tool. 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-,R-SK&F 38393,SK&F-38393,SKF 38393-A,SKF-38393,SKF38393,RSK&F 38393,SK&F 38393,SK&F38393,SKF 38393,SKF 38393 A,SKF 38393A

Related Publications

J H Abraini, and T Fechtali, and J C Rostain
January 1991, British journal of pharmacology,
J H Abraini, and T Fechtali, and J C Rostain
July 1988, British journal of pharmacology,
J H Abraini, and T Fechtali, and J C Rostain
May 1991, Brain research,
J H Abraini, and T Fechtali, and J C Rostain
April 1993, Mechanisms of ageing and development,
J H Abraini, and T Fechtali, and J C Rostain
November 1992, Neuroscience letters,
J H Abraini, and T Fechtali, and J C Rostain
December 1998, The Journal of pharmacy and pharmacology,
J H Abraini, and T Fechtali, and J C Rostain
April 1993, European journal of pharmacology,
J H Abraini, and T Fechtali, and J C Rostain
October 2004, Journal of neurochemistry,
J H Abraini, and T Fechtali, and J C Rostain
May 1990, Brain research,
J H Abraini, and T Fechtali, and J C Rostain
August 1998, Synapse (New York, N.Y.),
Copied contents to your clipboard!